Huatai Minke

Huatai Minke is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of next-generation cell therapies for oncology. The company's primary focus lies in Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR) engineered T-cell therapies designed to address unmet needs in both liquid and solid tumors. Its lead candidate, MC-1-1, is a dual-targeting CAR-T therapy aimed at B-cell malignancies, while its TCR-T pipeline includes programs targeting HPV-associated cancers. Huatai Minke utilizes proprietary platforms to optimize cell persistence and tumor infiltration, striving to provide curative options for cancer patients.